Answers are grounded in this paper and cite their sources.
"Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis." Amyloid, 24(sup1), pp. 58–59
No takes yet. Share an insight, caveat, or question.
Edwards et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: